. Seven hundred twenty-five biopsies performed in the outpatient setting were identified: There were 592 transplant and 133 native biopsies including 3 solitary kidney biopsies. All were performed under ultrasound guidance using a 16G or 18G needle, with freehand technique. In all patients with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m 2 desmopressin was administered. Patients were observed for 6h before discharge, with a complete blood count and urine test after 4 h. Major complications were haemorrhage requiring therapeutic intervention or transfusion. Minor complications were significant reduction in haemoglobin (Hb) levels (>10%), without need for transfusion or intervention and macrohaematuria. Results: There were 506 (69.8%) male patients. Average age was 50.3 ± 12.7 years. Indications for native kidney biopsy included nephrotic syndrome (39.8%), nephritic syndrome (42.9%), follow-up biopsy (15.8%), and other (1.5%). There were no major complications. A decline in Hb was observed in 72% of patients. Average Hb decline was 4.2 ± 6.3 g/L. In 10.1% patients there was >10% reduction in Hb level, with no evident bleeding, including by ultrasonography. In 2.5% of patients, macrohaematuria was present. In a multivariate analysis, male gender, lower eGFR, higher pre-biopsy Hb and native kidney biopsy were predictive for Hb decline. No therapeutic interventions were required. Conclusion: We found that kidney biopsy performed in an outpatient setting in select patients is only rarely associated with adverse events and is a safe procedure.
Introduction
Kidney biopsy is an essential part in the diagnosis and management of parenchymal renal diseases [1] . Since its introduction in the 1950s [2] , it remains the most exact diagnostic method for kidney parenchymal disease. It provides important information, altering treatment in a high percentage of cases [3] . The percutaneous kidney biopsy with real time ultrasound (US) guidance is the current standard of care [4, 5, 6] . Complications include macrohaematuria, haematoma, arteriovenous fistula, bleeding, or even nephrectomy. A systematic review and meta-analysis of percutaneous kidney biopsies from 1980 to 2011 (which included 34 studies with 9,474 biopsies that had met the inclusion criteria) was performed by Corapi et al. [7] , the rates of complications in the review were ranging from 3.5% for macrohaematuria (95% CI 0.3-14.5), over packed red blood cells (PRBC) transfusion in 0.9% (95% CI 0.4-1.5) to nephrectomy 0.01%. The rates of complications differ among centres [8, 9] . In re-DOI: 10 .1159/000484991 cent reports using real-time US guidance, complications associated with excessive bleeding rates are even more infrequent [6, 8, 10] .
To avoid adverse events, risk assessment remains crucial. In a recent review [7] , predictors of PRBC transfusion included the needle gauge (14 vs. 16 or 18) , sex (female), serum creatinine (≥180 μ/L), low haemoglobin (Hb) prior biopsy (≤120 g/L), acute kidney injury, high blood pressure, haemostasis abnormalities and anatomical abnormalities -horseshoe kidney, solitary kidney. Similar findings were reported in some other studies [9, 11, 12] . A historical contraindication, solitary kidney is today no longer reported as a contraindication in some centres [13] . As mentioned, the haemorrhagic diathesis present in uremic patients with advanced chronic kidney disease is associated with higher risk for bleeding. Desmopressin (DDAVP) is the most common agent used to treat or prevent bleeding in uremic patients [14, 15] . DDAVP improves haemostasis by releasing factor VIII: von Willebrand factor multimers from endothelial cells. DDAVP reverses uremic platelet dysfunction quickly (circa within one hour of intravenous injection) for a short duration of time (around 24 h) [16] .
With a better safety profile and technological development, kidney biopsy is performed in some centres as an outpatient procedure [4, 17] . In the outpatient setting, it is important to know the timing of complications to determine the optimal post-biopsy observation period. In a study form France [18] , 100% of complications occurred in outpatients within 8 h vs. 72% complications in inpatients, and 10% of inpatients had complications >24 h after biopsy. Historical data, prior to real-time US guidance, recommended longer observation periods [19] .
Another issue in renal biopsy is whether post biopsy imaging should be routine. In a recent review, the utility of post-biopsy ultrasonography or computed tomography has not been shown [4] . The presence of haematoma on post biopsy imaging does not predict clinically relevant complications, but the absence of haematoma has a high negative predictive value and imaging is proposed only when clinically needed [4, [20] [21] .
In our centre, biopsy is frequently performed as an outpatient procedure in suitable patients. We performed a retrospective observational study to evaluate the safety of biopsy in the outpatient setting.
Materials and Methods
We analysed native and transplant kidney biopsies performed at the University Hospital Merkur outpatient clinic from March 2013 to February 2017. In all, 725 biopsies performed in the outpatient setting were identified. There were 592 biopsies in transplant patients and 133 native kidney biopsies, including 3 solitary kidney biopsies. On the day of the biopsy, complete blood count, international normalized ratio/prothrombin time, activated partial thromboplastin time, serum creatinine, potassium and sodium were obtained. All medications that could increase bleeding risk (e.g., anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory drugs) were omitted for an appropriate period prior to biopsy. Polycystic kidney disease and radiological evidence of small atrophic kidneys were considered contraindications for biopsy. Abnormalities in haemostasis (prolonged prothrombin time, activated partial thromboplastin time, low platelet count) were contraindications for the procedure in the outpatient setting. Kidney function was determined using the 4-variable Modification of Diet in Renal Disease study equation to estimate glomerular filtration rate [22] . In all patients with estimated glomerular filtration rate (eGFR) <30-45 mL/min/1.73 m 2 , DDAVP (0.4 µg/kg body weight intravenous) was administered prior to the procedure. All biopsies were performed under US guidance using a 16G or 18G automated, spring-loaded needle with freehand technique. Bed rest for 4 h was prescribed to all patients. When patients were on bed rest, a 2-kilo sandbag was placed over (in kidney transplant patients) or under (native kidney) the biopsy site. Patients were observed for 6 h before discharge. A complete blood count and a urine test were performed after 4 h. Ultrasonography was performed upon attending clinician discretion. All patients were told to visit the emergency room if they developed any symptoms including pain, increasing heart rate, dizziness, or fever after discharge. Study outcomes were major and minor complications. Major complications were defined as haemorrhage requiring therapeutic intervention to stop bleeding and/or PRBC transfusion. Minor complications were defined as significant reduction in Hb levels (>10%), without need for PRBC transfusion and/or intervention to stop bleeding and macrohaematuria, without intervention to stop bleeding.
Statistical Analysis
Statistical analysis was performed using Statistica version 13.1 (Dell Software Inc., San Francisco, CA, USA). A p < 0.05 was considered to be significant. Data is expressed as the median and range, or mean with SD, as appropriate. Categorical variables are presented as frequency counts and percentages. The categorical values were compared using χ 2 test and continuous values between the 2 groups were compared using Student t test or Mann-Whitney test in case of not-normally distributed values. Correlations between the 2 continuous variables were tested by the Pearson correlation. A multiple regression analysis was performed to assess independent predictors of Hb decline. We included into multivariate analysis all variables that were associated with Hb decline in univariate analysis with p ≤ 0.1.
Results
There were 219 (30.2%) female and 506 (69.8%) male patients. The average age was 50.3 ± 12.7 years. Indications for native kidney biopsy included nephrotic syn- drome (39.8%), nephritic syndrome (42.9%), follow-up biopsy (15.8%), and other (1.5%). From 592 transplant biopsies, 72.8% were indication and 27.2% were protocol biopsies. The study population characteristics can be seen in Table 1 . The glomerular yield in 97.5% of biopsies was sufficient for analysis. A decrease in Hb was observed in 72% of patients. Average Hb decline post-biopsy was 4.2 ± 6.3 g/L (3.4 ± 5.2%; Table 1 ). There were no major complications requiring an intervention to stop bleeding or blood transfusion (Table 2 ). In 10.1% of patients, there was >10% reduction in Hb level, with no evident bleeding, including by US. In 2.5% of the patients, post-biopsy macrohaematuria was present, without requirement for intervention or blood transfusion. In 61.9% of patients, the decrease in Hb was less than 10%. In 28% of patients, there was no Hb decline after biopsy. Microhaematuria was present in 78.6% of patients. Eleven patients (1.5%) were hospitalized for overnight monitoring; all were discharged the next day. There were no therapeutic interventions required for biopsy complications. All patients included in the study had multiple follow-up visits, so we can be sure that there were no late complications.
The subgroup analysis between patients with native kidneys and transplanted is shown in Table 3 . Hb prior to biopsy, eGFR and the decline in Hb were higher in the native kidney group (p = 0.02, p < 0.001, and p = 0.04, respectively).
In univariate analysis, age, eGFR, needle gauge and the number of passes were not predictive for post-biopsy Hb decline. Pre-biopsy Hb (p = 0.037), male sex (p = 0.002) and native vs. transplant kidney biopsy (p = 0.04) were predictive of decline (Table 4 ). The multivariate analysis is shown in Table 5 .
Discussion
We analysed the safety of outpatient native and transplant kidney biopsies in a large tertiary renal centre. University Hospital Merkur has the largest kidney biopsy volume in Croatia. In our outpatient biopsy cohort, no severe complications leading to an intervention or to kidney loss were recorded during the period analysed. Complications that occurred were due to bleeding, similar as in other larger studies [23, 24] . The paucity of complications in the study can be partially explained by a large proportion (81.6%) of transplanted kidney biopsy in our cohort, as evidenced from the Table 5 . The anatomical localisation of the transplanted kidney makes them easier to visualise and to biopsy.
Another similar study of kidney allograft biopsies [25] showed 1.8% of complications, mostly comprising mild complications (0.7%) and only 0.19% life-threatening complications. The difference in the study was that it comprised all allograft biopsies from the institution in- Data is presented as number (percentage), mean ± SD, range. Hb, haemoglobin; eGFR, estimated glomerular filtration rate. cluding inpatient biopsies and early post-transplant biopsies, although the majority were in outpatient biopsies. A favourable safety profile for outpatient kidney allograft biopsies was also reported from a paediatric study [26] , with a 9.2% incidence of adverse events. A majority of those were micro-and macroscopic haematuria (8.4%).
Our results are similar to those of this study, with a complication rate of 2.5% for macroscopic haematuria without the need for intervention. Without the need for PRBC transfusion, 10.1% experienced a decline in postbiopsy Hb by greater than 10%. Only one patient had prolonged local bleeding, which resolved spontaneously.
All patients with eGFR <30-45 mL/min/1.73 m 2 received DDAVP to prevent bleeding, according to current recommendations in uremic patients [14, 15] . We also employed strict control of coagulation parameters, and omitting of antiplatelet or anticoagulant agents for several days prior to biopsy. This is different from some other centres' policies, where routine antiplatelet agent pausation had not been routinely advocated [27] . A possible reason of a low incidence of complications overall may be the use of 16G and 18G (in a majority of our patients), instead of 14G needles, as described in other studies, thus minimising the bleeding risk [7, 9, [28] [29] .
Our results show that outpatient biopsy, as performed in our centre is a safe procedure. Crucial to a good safety profile may be large centre volume, careful risk assessment prior to biopsy and the selection of lower risk patients for outpatient biopsy.
Our study has limitations. This is a retrospective, single-centre study. However, patient data and biopsy complications were prospectively recorded, minimising underreporting of complications. Nevertheless, for a definite conclusion about the safety of outpatient kidney biopsy, a larger sample size and a multi-centre prospective study would be necessary.
We found that kidney biopsy performed in an outpatient setting in select patients is only rarely associated with adverse events and is a safe procedure.
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